The Pharma Data

NOVEMBER 4, 2020

Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. This press release and further information about Alexion can be found at: www.alexion.com. Forward-Looking Statement.

Antibody 52

Antibody Containment Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 30, 2021

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. reduction in LDL-C from baseline to Day 510 compared with placebo ( P < 0001) 1.

RNA 52

RNA Trials Production Containment 52

The Pharma Data

JANUARY 12, 2021

Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. This press release and further information about Alexion can be found at: www.alexion.com.

Containment 52

Containment Development Sales Production 52

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. It contains the antiviral medications nirmatrelvir and ritonavir.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

OCTOBER 25, 2020

Abiomed has a long-established track record of bringing to market improved options to support physicians with innovative technology like Breethe, which is designed to provide advanced respiratory and cardiac support,” said Bartley Griffith, MD, the Hales Distinguished Professor of Surgery at University of Maryland, School of Medicine.

Cardiology 52

Cardiology FDA Approval Development Engineer 52

XTalks

FEBRUARY 8, 2024

Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries. Both drugs continue to dominate the diabetes and GLP-1 markets. It’s been widely marketed and is considered a leading medication in the SGLT2 inhibitor class. percent in the fourth quarter and decreased 56.7

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer. In addition, the cascades can also contain beta emissions.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

SEPTEMBER 15, 2020

The team shared results from a Phase 2a study that was conducted by Akcea Therapeutics/Ionis Pharmaceuticals and previously disclosed at the recent European Society of Cardiology Congress 2020. Disclosure Notice: The information contained in this release is as of September 15, 2020. and -50.4%

Vaccine 52

Vaccine Vaccination Gene Therapy Trials 52

The Pharma Data

NOVEMBER 4, 2020

Amarin’s decision to continue to invest in expanding the market for VASCEPA also reflects its confidence in its manufacturing processes, which the company has built over a decade to achieve consistent, high-quality, stable supply to support anticipated global demand. commercial team.

Sales 40

Sales Production Marketing Cardiology 40

The Pharma Data

APRIL 26, 2021

(USD 789 million, +34% cc) sustained strong growth with increased patient share across markets, driven by demand as the essential first choice therapy for heart failure patients. USD 319 million, +81% cc) had a strong quarter with growth driven by Europe and Emerging Growth Markets, as well as ongoing geographic expansion.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

OCTOBER 29, 2020

Established ULTOMIRIS as new standard of care in PNH ahead of set goal, with more than 70% patient conversion from SOLIRIS ® (eculizumab) in 3 largest markets – U.S. Marketable securities. Received U.S. Germany & Japan. Initiated Phase 3 program for CAEL-101 in AL amyloidosis in collaboration with Caelum Biosciences.

Sales 40

Sales Clinical Trials Clinical Trials Production 40